Linical Co., Ltd. ((JP:2183)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Linical Co., Ltd. is collaborating on a groundbreaking clinical study titled ‘A Single Center, Open Label, Single Group, Phase 1/2a Clinical Study to Evaluate the Safety and Exploratory Efficacy of Transplantation Therapy Using PSA-NCAM(+) NPC Derived From hESC Line in AIS-A Level of Sub-acute SCI.’ The study aims to assess the safety and preliminary effectiveness of using neural precursor cells derived from human embryonic stem cells to treat paralysis and related symptoms from sub-acute spinal cord injuries.
The intervention involves the experimental administration of PSA-NCAM(+) NPC, a biological treatment using neural precursor cells, delivered via intrathecal injection to patients with complete spinal cord lesions at the C4-C7 levels.
This interventional study follows a single-group assignment model without masking, focusing on treatment as its primary purpose. All participants receive the same intervention, allowing researchers to closely monitor the effects of the treatment.
Key dates for the study include its initial submission on February 24, 2021, and the most recent update on May 14, 2025. These dates are crucial for tracking the study’s progress and ensuring transparency in its development.
The study’s progress could significantly impact Linical Co., Ltd.’s stock performance and investor sentiment, especially if the results demonstrate promising efficacy and safety. This could position the company as a leader in innovative spinal cord injury treatments, potentially affecting competitors in the biotechnology sector.
The study is currently ongoing, with further details available on the ClinicalTrials portal.